Endovascular Stroke Trials Why We Must Enroll All Eligible Patients

Stroke Reports Sunday, December 15th, 2013

STROKEAHA: November 12, 2013

Is it appropriate to enroll into a clinical trial (and hence randomize to either medical or endovascular therapy) a 45-year-old patient who presents within 3 hours of onset of disabling symptoms resulting from a left M1 occlusion? This is the question many of us have faced in the course of the past few months because multiple new trials of endovascular stroke therapy have been launched on the heels of the neutral Interventional Management of Stroke (IMS)-III, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR-RESCUE), and Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS) trials.1–3 The recently published IMS-III, MR-RESCUE, and SYNTHESIS trials have raised important questions related to efficacy of intra-arterial treatment.  read more

Sign Up Now
National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2012 National Minority Quality Forum, Inc. All Rights Reserved.